Sunitinib Malate is a tyrosine kinase inhibitor drug used in cancer therapy. It was first approved by the US FDA in 2006 and has since become an important treatment option for various types of cancers, including renal cell carcinoma, gastrointestinal stromal tumor, and pancreatic neuroendocrine tumor.
Chemical Name
The chemical name of Sunitinib Malate is (Z)-butenedioic acid; 2-(2-diethylaminoethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide.
Molecular Formula
The molecular formula of Sunitinib Malate is C22H27FN4O2.C4H6O5.
Formula Weight
The formula weight of Sunitinib Malate is 532.61 g/mol.
CAS No.
The CAS number of Sunitinib Malate is 341031-54-7.
Top Ten Keywords from Google and Synonyms
Synonyms: Sutent, SU11248, Sunitinibum, N-(2-(Diethylamino)ethyl)-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Health Benefits of Sunitinib Malate
Sunitinib Malate is primarily used as a cancer therapy drug. It works by inhibiting the activity of multiple receptor tyrosine kinases (RTKs), which play a critical role in tumor growth and angiogenesis. By blocking RTKs, Sunitinib Malate reduces the supply of blood and nutrients to cancer cells, thereby slowing down their growth and spread.
Potential Effects
Clinical studies have shown that Sunitinib Malate can effectively treat several different types of cancer, including:
Product Mechanism
Sunitinib Malate is a multi-targeted receptor tyrosine kinase inhibitor, which means it blocks the activity of several different RTKs at once. These RTKs include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and Fms-like tyrosine kinase 3 (FLT3). By blocking these receptors, Sunitinib Malate reduces the growth and spread of cancer cells.
Safety
Sunitinib Malate is generally safe and well-tolerated by patients. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, diarrhea, vomiting, headaches, and skin discoloration. More severe side effects may occur in some patients, such as high blood pressure, heart problems, and liver damage. Patients should be closely monitored for any adverse reactions while taking Sunitinib Malate.
Side Effects
The most common side effects of Sunitinib Malate include:
More severe side effects may occur in some patients, such as:
Dosing Information
The dosing of Sunitinib Malate depends on the type of cancer being treated and other individual factors. It is typically administered orally in capsule form, once daily for four weeks followed by a two-week rest period. The cycle is then repeated until the cancer has progressed or the patient experiences unacceptable toxicity.
Conclusion
In conclusion, Sunitinib Malate is a valuable tool in the fight against cancer. As a multi-targeted receptor tyrosine kinase inhibitor, it blocks the activity of several different RTKs
